Many individuals with type 2 diabetes produce abnormally low levels of a gut hormone called GLP-1, which normally stimulates insulin release from the pancreas.
Many individuals with type 2 diabetes produce abnormally low levels of a gut hormone called GLP-1, which normally stimulates insulin release from the pancreas. Now a new study shows that GLP-1 production by special cells in the gut known as L-cells can be restored in patients with recent onset type 2 diabetes following three to 12 months of treatment with liraglutide, a drug that is similar to native GLP-1.
“This study shows that chronic liraglutide therapy induces a robust enhancement of GLP-1 secretion by the body that may hold implications for the long-term effects of this medication in patients," said Dr. Ravi Retnakaran, senior author of the Diabetes, Obesity and Metabolism study.
Additional Information
Link to study: http://onlinelibrary.wiley.com/doi/10.1111/dom.12838/abstract
About Journal
Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics is the only interdisciplinary journal for high-quality research and reviews in the areas of diabetes, obesity and metabolism. It focuses on clinical and experimental pharmacology and therapeutics in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems.
Penny Smith
+44 (0)1243 770171
sciencenewsroom@wiley.com